Posted by Michael Wonder on 28 Aug 2018
Feedback encouraged to allow use of life extending treatment on NHS for those with blood cancer
28 August 2018 - CAR-T considered to be an exciting innovation which can cure some patients but very expensive.
NICE has invited comments and further evidence on a new treatment for aggressive subtypes of non-Hodgkin lymphoma called diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma that could lead to it being made available for use on the NHS.
NICE’s draft guidance, published today, recommends against the use of axicabtagene ciloleucel, also called Yescarta and made by Kite Pharma, in England.
